Dr. Lal PathLabs Dirección

Dirección controles de criterios 2/4

El CEO de Dr. Lal PathLabs' es Bharath Uppiliappan, nombrado en Apr 2020, tiene una permanencia de 4.08 años. posee directamente un 0.015% de las acciones de la empresa, con un valor de ₹29.65M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 5.1 años, respectivamente.

Información clave

Bharath Uppiliappan

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.1yrs
Participación del CEO	0.02%
Permanencia media de la dirección	4.1yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

May 25

Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?

Apr 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) A Risky Investment?

Feb 17

With EPS Growth And More, Dr. Lal PathLabs (NSE:LALPATHLAB) Is Interesting

Jan 20

Why You Should Care About Dr. Lal PathLabs' (NSE:LALPATHLAB) Strong Returns On Capital

Dec 06

Here's Why I Think Dr. Lal PathLabs (NSE:LALPATHLAB) Might Deserve Your Attention Today

Oct 13

CEO

Bharath Uppiliappan

4.1yrs

Permanencia

Mr. Bharath Uppiliappan has been Chief Executive Officer of Dr. Lal PathLabs Limited since April 1, 2020. He served as CEO of India Business at Dr. Lal PathLabs Limited since 2018 until April 1, 2020 and h...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Arvind Lal	Executive Chairman	29.3yrs	₹28.24m	33.48% ₹ 64.5b
Om Manchanda	MD & Director	4.1yrs	₹44.42m	1.16% ₹ 2.2b
Vandana Lal	Executive Director	no data	₹22.65m	19.36% ₹ 37.3b
Bharath Uppiliappan	Chief Executive Officer	4.1yrs	sin datos	0.015% ₹ 29.0m
Ved Goel	Group Chief Financial Officer	5.8yrs	₹7.30m	0.012% ₹ 22.6m
Jai Meena	Chief Operating Officer	2.1yrs	sin datos	sin datos
Munender Soperna	Chief Information & Digital Officer	9.9yrs	sin datos	0.034% ₹ 64.9m
Vinay Gujral	Company Secretary & Compliance Officer	1.1yrs	sin datos	sin datos
Manoj Garg	Group Chief Human Resources Officer	9.6yrs	sin datos	0.037% ₹ 71.2m
Shankha Banerjee	Chief Executive Officer of Group & Associates Companies	no data	sin datos	0.033% ₹ 63.2m

4.1yrs

Permanencia media

62.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LALPATHLAB se considera experimentado (4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Arvind Lal	Executive Chairman	29.3yrs	₹28.24m	33.48% ₹ 64.5b
Om Manchanda	MD & Director	13.3yrs	₹44.42m	1.16% ₹ 2.2b
Vandana Lal	Executive Director	29.3yrs	₹22.65m	19.36% ₹ 37.3b
Arun Duggal	Lead Independent Director	1.3yrs	₹250.00k	sin datos
Rajit Mehta	Independent Director	less than a year	sin datos	sin datos
Rahul Sharma	Non Executive Director	18.8yrs	₹1.87m	0.037% ₹ 70.7m
Rohit Bhasin	Independent Non-Executive Director	1.5yrs	₹770.00k	sin datos
Somya Satsangi	Independent Director	5.3yrs	₹2.13m	sin datos
Archana Erdmann	Non-Executive Director	5yrs	₹1.47m	2.04% ₹ 3.9b
Gurinder Singh Kalra	Independent Director	less than a year	sin datos	sin datos

5.1yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de LALPATHLAB se considera experimentada (5 años de antigüedad promedio).

Dr. Lal PathLabs Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

MD & Director recently sold ₹43m worth of stock

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Recent updates

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

MD & Director recently sold ₹41m worth of stock

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Chief Executive Officer recently sold ₹3.6m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹61m worth of stock

MD & Director recently sold ₹57m worth of stock

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2023 Results on Nov 08, 2022

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

MD & Director recently sold ₹33m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Non Executive Director recently sold ₹2.5m worth of stock

MD & Director recently sold ₹117m worth of stock

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, Payable on or Before August 26, 2022

First quarter 2023 earnings: EPS misses analyst expectations

Dr. Lal PathLabs Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Non-Executive Director recently sold ₹164m worth of stock

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Price target decreased to ₹2,536

Upcoming dividend of ₹6.00 per share

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Dr. Lal Pathlabs Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022